Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 4.7% in December: Crecon Report
February 12, 2014
- Asahi Kasei Pharma Completes 2nd Manufacturing Facility at Nagoya Pharmaceuticals Plant
February 12, 2014
- Novartis Appoints Former Tokyo High Court Judge to Head Independent Commission to Investigate Scandal Over SIGN Study
February 10, 2014
- Transdermal Parkinson’s Disease Treatment Ropinirole Shows Significant Difference in PII Study: Hisamitsu
February 10, 2014
- Mitsubishi Chemical to Set Up New Healthcare Firm
February 7, 2014
- MTPC Appoints Development Division Manager as New Representative Director
February 7, 2014
- Takeda CFO Says Midterm Strategy Not Affected by Halt of TAK-875 Trials
February 7, 2014
- Astellas to Bring Global Development, Regulatory Affairs Functions Under Control of Chief Medical Officer
February 7, 2014
- JCR, GSK Ink Research Support Agreement to Establish New Technology
February 6, 2014
- Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
- Fujifilm Pharma Gets Japan Distribution Rights for Sosei’s Oropharyngeal Candidiasis Drug
February 6, 2014
- Kyowa Kirin Begins Japan PIII Trial of ARQ 197 for Hepatocellular Cancer
February 6, 2014
- Eisai to File Lenvatinib for Approval in Japan, US, Europe as Early as June
February 6, 2014
- NDA for Lorcaserin Expected to Be Filed in Japan in FY2016 or Later: Eisai
February 5, 2014
- 396 Eisai Workers Take Voluntary Retirement, FY2013 Net Profit Forecast Revised Downward
February 5, 2014
- DSP Expands Collaboration with Edison for Development of Mitochondrial Disease Treatment
February 5, 2014
- Kyowa Kirin to Integrate Research and Development Divisions
February 4, 2014
- Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
- Kyowa Kirin Drug Prices Expected to Slip by 7% Due to NHI Price Revision
February 4, 2014
- Asahi Kasei Pharma to Discontinue Development of Teribone Transdermal Patch Formulation in Japan
February 4, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…